uploads/2018/07/Chart-06-1.jpg

Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018

By

Updated

Neuroscience products

Eli Lilly & Co.’s (LLY) Human Pharmaceuticals business includes neuroscience products such as Cymbalta, Strattera, and Zyprexa. The overall sales for its neuroscience products declined in the second quarter, driven by lower sales of Cymbalta, Strattera, Zyprexa, and other drugs. The chart below shows its revenues for neuroscience products since the first quarter of 2017.

Article continues below advertisement

Strattera

Strattera, a drug for the treatment of ADHD (attention-deficit/hyperactivity disorder), reported revenues of $114.2 million during the second quarter. This represents a 39.0% YoY (year-over-year) decline in revenues, compared to $186.6 million during the second quarter of 2017.

This decline was driven by lower sales in its US markets, and it was partially offset by strong sales from its international markets. The drug’s US sales decreased to $16.9 million, and its international sales increased to $97.3 million during the quarter.

Cymbalta

Cymbalta, an antidepressant drug, reported revenues of $181.9 million during the second quarter, a 12.0% YoY decline in revenues compared to $206.6 million during the second quarter of 2017. 

This decline was driven by lower sales from its US markets, and it was partially offset by strong growth in international sales. Cymbalta’s US sales declined to $12.6 million, while its sales from international markets increased to $169.4 million during the quarter.

Zyprexa

Zyprexa, an antipsychotic drug, reported revenues of $128.0 million during the second quarter, a 9.0% YoY decline in revenues compared to $140.8 million during the second quarter of 2017. This decline in revenues was driven by lower sales in its US and international markets. The drug’s US sales decreased to $11.8 million, while its international sales declined to $116.2 million during the quarter.

The iShares Evolved US Innovative Healthcare ETF (IEIH) holds 5.9% of its total investments in Eli Lilly (LLY), 6.4% in Pfizer (PFE), 9.1% in Johnson & Johnson (JNJ), and 4.8% in Celgene (CELG).

Advertisement

More From Market Realist